Repositorio
Institucional

Roa, Juan C.

Garcia, Patricia

Leal, Pamela

Alvarez, Hector

Brebi, Priscilla

Ili, Carmen

Tapia, Oscar

Connective Tissue Growth Factor Immunohistochemical Expression Is Associated With Gallbladder Cancer Progression

COLL AMER PATHOLOGISTS

ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE

en

Context.-Gallbladder cancer (GBC) is an aggressive neoplasia associated with late diagnosis, unsatisfactory treatment, and poor prognosis. Molecular mechanisms involved in GBC pathogenesis remain poorly understood. Connective tissue growth factor (CTGF) is thought to play a role in the pathologic processes and is overexpressed in several human cancers, including GBC. No information is available about CTGF expression in early stages of gallbladder carcinogenesis. Objective.-To evaluate the expression level of CTGF in benign and malignant lesions of gallbladder and its correlation with clinicopathologic features and GBC prognosis. Design.-Connective tissue growth factor protein was examined by immunohistochemistry on tissue microarrays containing tissue samples of chronic cholecystitis (n = 51), dysplasia (n = 15), and GBC (n = 169). The samples were scored according to intensity of staining as low/absent and high CTGF expressers. Statistical analysis was performed using the chi(2) test or Fisher exact probability test with a significance level of P < .05. Survival analysis was assessed by the Kaplan-Meier method and the log-rank test. Results.-Connective tissue growth factor expression showed a progressive increase from chronic cholecystitis to dysplasia and then to early and advanced carcinoma. Immunohistochemical expression (score >= 2) was significantly higher in advanced tumors, in comparison with chronic cholecystitis (P < .001) and dysplasia (P = .03). High levels of CTGF expression correlated with better survival (P = .04). Conclusions.-Our results suggest a role for CTGF in GBC progression and a positive association with better prognosis. In addition, they underscore the importance of considering the involvement of inflammation on GBC development.

Artículo original

Supported by FONDECYT project 1090171, DIUFRO project DI09-0082, and grant for support of doctoral thesis CONICYT-24090177.

Este trabajo ha sido financiado por el proyecto FONDECYT 1090171, el proyecto DIUFRO DI09-0082 y la beca de apoyo a la tesis doctoral CONICYT-24090177.

10.5858/arpa.2011-0628-OA

pdf

CHRONIC INFLAMMATION

PROGNOSTIC-FACTORS

SURGICAL-TREATMENT

CARCINOMA

CTGF

MARKER

CYR61

CYCLOOXYGENASE-2

OVEREXPRESSION

METASTASIS

INFLAMACIÓN CRÓNICA

FACTORES PRONÓSTICOS

TRATAMIENTO QUIRÚRGICO

CARCINOMA

CTGF

MARCADOR

CYR61

CICLOXIGENASA-2

SOBREEXPRESIÓN

METÁSTASIS

CHRONIC INFLAMMATION

PROGNOSTIC-FACTORS

SURGICAL-TREATMENT

CARCINOMA

CTGF

MARKER

CYR61

CYCLOOXYGENASE-2

OVEREXPRESSION

METASTASIS

INFLAMACIÓN CRÓNICA

FACTORES PRONÓSTICOS

TRATAMIENTO QUIRÚRGICO

CARCINOMA

CTGF

MARCADOR

CYR61

CICLOXIGENASA-2

SOBREEXPRESIÓN

METÁSTASIS

Gastroenterología y Hepatología

Oncología

Patología

Connective Tissue Growth Factor Immunohistochemical Expression Is Associated With Gallbladder Cancer Progression

ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE

dorada

verde

acceso abierto

acceso abierto

PMID 23368866

en

Artículo original

versión publicada

ANID CONICYT FONDECYT 1090171#UFRO DI09-0082#ANID CONICYT 24090177

ANID CONICYT FONDECYT 1090171

UFRO DI09-0082

ANID CONICYT 24090177

COLL AMER PATHOLOGISTS

0003-9985

245

250

Tecnología de laboratorio médico

Medicina, investigación y experimentación

Patología

Medical Laboratory Technology

Medicine, Research & Experimental

Pathology

pdf

WOS:000319776000015